Iceland· IS-EU/1/07/403/001-002
Atriance
A nelarabine product containing nelarabinum inn, registered in Iceland by Sandoz Pharmaceuticals d.d.. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Nelarabine is registered in 13 of 19 countries.
Countries holding a registration under ATC L01BB07 (nelarabine), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Nelarabine · ATC L01BB07
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Nelarabinum INN
- Manufacturer
- Sandoz Pharmaceuticals d.d.
- Country
- Iceland (IS)
- ATC code
- L01BB07
- ATC class
- Nelarabine
- Defined daily dose
- 0.39 g, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean98298450 ml x1 hglISK 46529
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
201 interactions on record for nelarabine.
Graded by severity as the source publishes them — 35 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nelarabine · interactions on record
201 records
- 35 severe
- 166 moderate
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nelarabine in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandAtrianceOrifarm Oy
- CzechiaATRIANCESandoz Pharmaceuticals d.d., Ljubljana
- SpainATRIANCE 5 MG/ML SOLUCION PARA PERFUSIONSandoz Pharmaceuticals D.D.
- IrelandATRIANCE 5mg/ml Solution for InfusionSandoz Pharmaceuticals d.d.
- PolandAtrianceSandoz Pharmaceuticals d.d.
- SwedenATRIANCE 5 mg/ml Infusionsvätska, lösningSandoz Pharmaceuticals d.d.
- BelgiumAtriance 5 mg/mlSandoz Pharmaceuticals
- United StatesNelarabineSagent Pharmaceuticals
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Atriance
- Norway · Atriance
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d2dbfa7c-98e1-4f07-94af-8a378ba6f3b0 GET /v1/drugs/d2dbfa7c-98e1-4f07-94af-8a378ba6f3b0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Innrennslislyf, lausn",
"source": "lyfjastofnun",
"atc_raw": "L01BB07",
"marketed": false,
"strength": "5 mg/ml",
"ma_number": "EU/1/07/403/001-002",
"substance": "Nelarabinum INN",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "39345"
}See everything about nelarabine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.